Traditionally, male contraception has consisted of either barrier methods, such as condoms, or vasectomy. However, in recent years, we have made great strides in the basic science and clinical medicine to better understand the feedback mechanisms and physiology of the male reproductive system. These advances have enabled the development of several nonsurgical, hormonal, reversible, well-tolerated alternatives for male contraception. Men are more likely now than ever to participate in the choice of contraceptive techniques. This review will discuss the current status and recent developments in nonsurgical hormonal male contraception, a field that has been historically limited by social, financial and physiological challenges.
Male contraception has traditionally consisted of either barrier methods, such as condoms or vasectomy. Vasectomy is a permanent, expensive, surgical solution with very low failure rates of 1/2000. 1 Condoms are a less desirable option and with typical and ideal use results in a 14 and 3% yearly pregnancy rate, respectively. The ideal contraceptive would be 100% effective, reversible, noninvasive, affordable, with no short-or long-term side effects.
Men are more likely now than ever to participate in the choice of contraceptive techniques, although there are notable variations between population groups and cultures. 2 Furthermore, an international study involving 450 women also suggested that women would both trust and welcome their male partner to take a more active role in contraception. 3 Approximately half of all conceptions are unplanned, resulting in unintended pregnancies and subsequent elective terminations. 4 Therefore, it has become quite important to develop less invasive, more tolerable and more reversible methods of male contraception that have a success rate similar or better than female hormonal contraception. This review will discuss the current status and recent developments in male contraception, a field that has been historically limited by social, financial and physiological challenges.
Review of hypothalamic-pituitarygonadal axis and spermatogenesis
An understanding of the endocrinology of male reproduction, specifically the male hypothalamicpituitary-gonadal axis and the basics of spermatogenesis is required to understand the methodologies used for male contraception.
The hypothalamic-pituitary-gonadal pathway is regulated through negative feedback by downstream products as summarized in Figure 1 . Spermatogenesis is regulated by the pulsatile release of gonadotropin-releasing hormone (GnRH) from the arcuate nucleus of the hypothalamus, which stimulates the anterior pituitary to episodically release folliclestimulating hormone (FSH) and luteinizing hormone (LH). LH stimulates the Leydig cells to produce testosterone, which has a local effect on the interstitium and seminiferous tubules and results in sperm production and maturation. This effect is manifested by very high intratesticular testosterone compared with the bloodstream. FSH exerts its effect directly on the Sertoli cells to promote spermatogenesis. Testosterone and estradiol (converted through aromatase in the testis interstitium) are direct negative feedback modulators of GnRH, LH and FSH. Aromatase inhibition increases FSH levels suggesting that FSH regulation is more dependent on estradiol than testosterone. 5, 6 Other substances have a role in this important neuroendocrine negative feedback pathway. Studies have shown that kisspeptins, a group of amino-acid peptides, and their G-protein-coupled receptor (GPR54) have a critical function in the secretion of GnRH and the negative feedback of testosterone and estradiol on the hypothalamus. Administration of kisspeptin has been shown to increase GnRH secretion in neuronal cell lines. 7 Furthermore, although acute administration of kisspeptin seems to increase LH, FSH and testosterone secretion, chronic administration lowers serum LH levels in monkeys. 8, 9 Manipulation of the kisspeptin-GPR54 pathway represents another potential target for future male contraceptive therapy. 8 Complex interplay between testosterone, FSH and other factors is important for normal spermatogenesis. Sertoli cells are part of the seminiferous tubules that are activated by FSH and function to provide the optimal environment for the developing sperm cells throughout spermatogenesis. Inhibin B represents a nonsteroidal substance released by Sertoli cells after puberty and functions as a negative feedback on FSH secretion. Inhibin B could potentially be another indirect target to suppress spermatogenesis. However, the role of inhibin in FSH suppression and spermatogenesis is unclear, as low levels of inhibin are still present with LH-receptor mutations and chronic FSH administration. 8, 10, 11 Progesterone receptors are seen in the hypothalamus, pituitary and testis. It appears that progesterone affects gonadotropins via the hypothalamicpituitary-testis axis, however, they may function directly on the testis as well. 12, 13 It is clear that in normal sperm-producing men, intratesticular testosterone levels are 100-fold higher than in serum. [14] [15] [16] [17] [18] Interestingly, LH-receptor-deficient mice can support some level of spermatogenesis, but use of an androgen receptor antagonist such as flutamide will suppress spermatogenesis completely. [19] [20] [21] The role of dihydrotestosterone, a potent metabolite of testosterone, in spermatogenesis appears to be less clear. A decrease in dihydrotestosterone levels does not seem to cause a significant drop in sperm production. 22 On a cellular and receptor level, androgen receptors are found in multiple cell sites within the testes, specifically immature germ cells, smooth muscle cells, myoid cells, Sertoli and Leydig cells. Cell-specific effects on androgen receptors may affect spermatogenesis. In Sertoli cell and Leydig cell androgen receptor-specific knockout mice, spermatogenesis is impaired. [23] [24] [25] [26] In contrast, androgen receptors on germ cells and myoid cells appears to be less important in spermatogenesis as knock out models in these situations, do not impair spermatogenesis in a major way. 23, 27 Compounds that are cell specific and influence Sertoli and Leydig cell androgen receptors could potentially be an excellent site of future male contraceptive thoughts. As described earlier, complete blockage of the androgen receptor with flutamide suppresses spermatogenesis. 28 Molecules that follow this pathway, but may be more specific and do not have the significant negative side effects of flutamide, may be valuable potential contraceptive targets.
Spermatogenesis is hormone dependent. Spermatogonia divide in 16-day intervals to form B spermatogonia, which will differentiate and progress through spermatogenesis. Other B spermatogonia will renew to form new precursor stem cells. Type B spermatogonia that differentiate will divide mitotically to form primary spermatocytes and these will undergo meiosis to secondary spermatocytes and round spermatids. The round spermatids will then undergo a process of conformational change into mature spermatids. In this process, they will undergo extensive changes in cytoplasm and nucleus, form an acrosome, flagellum and cytoplasmic organelles undergo changes to form a mature spermatozooan. This process requires approximately 64 days. High levels of intratesticular testosterone are required for this to occur. Hypophysectomy results in testis atrophy, but not Update on male hormonal contraception GJ Manetti and SC Honig complete depletion of germ cells, and blocks maturation and causes interference with germ cell proliferation. 29 When testosterone microspheres are injected into the testes of GnRH agonist-treated rats, almost completely normal spermatogenesis occur. 30 Based on this data, the roles of FSH and LH are not completely clear in the renewal of spermatogenesis. It appears that high intratesticular testosterone will initiate and maintain qualitative spermatogenesis. This can be initiated by LH stimulation or exogenous hCG; however, the role of FSH is less clear. Men with FSH receptor defects can be fertile, although spermatogenesis appears to be significantly impaired. FSH also can initiate spermatogenesis in pubertal men and reinitiate sperm production in animals that have undergone hypophysectomy. In patients with hypogonadotropic hypogonadism, FSH provides for optimized spermatogenesis in some but not all cases. It appears that the combination of FSH and high intratesticular testosterone is important for normal sperm production. 31 It appears that suppression of gonadotropins has a direct effect on germ cell apoptosis and this is the mechanism of suppression. 32 All these data are valuable as we evaluate the effects of different agents as male contraceptives.
Endocrinological treatment strategies for male contraception are listed in Table 1 and are shown in Figure 2 . Taking advantage of disruption of negative feedback mechanisms and interruption of normal pulsatile release of hormones are the mainstay of therapeutic options.
Hormonal treatment
The concept of male hormonal manipulation for contraception predated the era of female hormonal contraception by 20 years. In 1939, two investigators independently tested testosterone for suppression of spermatogenesis. 33, 34 Since then, female birth control pills have dominated the contraceptive market. It has been difficult to equal or improve on the safety, efficacy and reversibility of female birth control pills, as the bar has been set quite high. The failure rate of 1/2000 with vasectomy has set the bar very high as well. 1 In 2007, the 10th summit group published their updated recommendations for regulatory approval for hormonal male contraception. This international group was designed to review the status of clinical development projects for male hormonal contraception. 35 Although much has been published regarding the safety and efficacy of different methods of hormone-based male contraception, there has been no clear consensus as to how to measure successful suppression of spermatogenesis, inclusion criteria for studies, reversibility of treatment, length of study to determine safety and power of study necessary to prove efficacy. Table 2 lists the recommendations and guidelines for male contraceptive options. The ideal hormone-based male contraceptive would be safe, affordable, 100% effective, reversible, with no short-or long-term side effects. Such a drug does not exist now.
There have been several review articles published in the past few years on male contraception. 8, [36] [37] [38] [39] [40] [41] [42] [43] The purpose of this review was to summarize the published data regarding hormone-based male contraceptive treatment options.
Testosterone alone
In 1939, independent studies on male contraception were performed by Heckel 33 and McCullagh and McGurl 34 and with short-acting testosterone propionate. Subsequent studies revealed reversible azoospermia by 60 days in some patients with daily use of 25 mg i.m. testosterone propionate. 44 Improved frequency and dosage were achieved with the advent of longer-acting testosterone enanthate (TE), spurring interest in studies with an improved delivery frequency.
The WHO (World Health Organization) in conjunction with the Contraceptive Research and Development program conducted two large multicenter studies on TE. In the initial multicenter study conducted in seven countries, subjects received 200 mg TE i.m. weekly and used no other contraception for 1 year once sperm concentrations fell below 3 million per ml. 45 This study revealed that 70% of 271 patients became azoospermic after 6 months of treatment. The mean time to azoospermia was 3 months. The azoospermic patients were enrolled in a 12-month efficacy phase, where one pregnancy occurred. Sperm reappeared in the Update on male hormonal contraception GJ Manetti and SC Honig ejaculate in 11 patients. Once the testosterone was discontinued, the mean time to sperm recovery was 3.7 months. Of note, this international study revealed that 91% of Asian and 60% of Caucasian patients became azoospermic, suggesting an ethnic difference in endocrine response. This difference has been seen in subsequent studies. Possible explanations include fivefold differences a-reductase levels in these groups, 46 lower baseline testosterone levels, differing susceptibility of the gonadotropic axis to testosterone and/or the rate of metabolic clearance of this hormone. One recent study by Kornmann et al. 47 suggest that differences in body fat content may have a central role in the discrepancy between the sperm suppression rates of Asians and Caucasians. This investigation evaluated 40 Caucasian men and showed that men with high fat mass had an impaired relative decline in LH and FSH in response to testosterone administration (testosterone propionate and testosterone undecanoate (TU)). They suggest that fat content may be important in differences that occur. Adjustments in the dosing or frequency of injections in obese men may overcome this problem. This may explain why suppression differs in different ethnic populations. Although semen analysis was not performed in this relatively small study, it Figure 2 Male hormonal contraceptive (MHC) regimens (compromising androgens alone or in combination with progestins or GnRH antagonists) act to inhibit the hypothalamic-pituitary-testicular axis. Exogenous testosterone (T) must be administered to maintain virilization and suppress GnRH, FSH and LH levels and thereby intratesticular androgen production (testosterone and dihydrotestosterone (DHT) (percent baseline levels following MHC administration are shown in brackets). Reduction in Sertoli cell FSH and androgen receptor (AR) activation results in marked inhibition of spermatogenesis, mainly the maturation of type A pale (Ap) to type B (B) spermatogonia and of sperm release (spermiation). MHC agents that have undergone some assessment in humans include progestins, GnRH antagonists, 7a-methyl-19-nortestosteone (MENT) and 5a reductase inhibitors with their sites of actions marked. Potential but untrialled MHC agents (selective androgen response modulators (SARMs) that target inhibition of the Sertoli cell AR, FSH-R antagonists, agents to inhibit spermiogenesis and spermiation) appear in hatched boxes. Germ-cell subtypes include type A pale spermatogonia (Ap); type B spermatogonia (B); leptotene-zygotene spermatocytes (L-Z); pachytene spermatocytes (PS); steps 1-2 round spermatids (rST); steps 3-6 elongating spermatids (El), steps 7-8 elongated spermatids (Eld) and spermatozoa (S). Source: Matthiesson and McLachlan. 42 Reprinted with permission from Oxford University Press.
Update on male hormonal contraception GJ Manetti and SC Honig provides insight that may assist in the development of patient-specific male contraceptives that will be more universally marketable. The second WHO testosterone study was performed as a 15-center, 9-country study with 399 volunteers. Among them, 98% suppressed spermatogenesis to o3 million sperms per ml with weekly 100 mg i.m. TE after induction phase with 200 mg i.m. TE. 48 There was a significant difference in pregnancy rates between azoospermic patients (1.4 pregnancy per 100 person-years) and patients between 0.1 and 3 million sperms per ml (8.1 pregnancies per 100 person-years). Approximately 25% of patients discontinued the study due to personal reasons, dislike of injections or for medical reasons. This study confirmed the relative efficacy of treatment and was the groundwork for further studies with different longer-acting testosterone regimens.
A phase 2, multicenter study was performed with a longer-acting monthly injections of TU in 380 Chinese men. Among them, 76% of patients suppressed enough to enter the initiation phase. If suppression was to azoospermia or o3 million sperms per ml, there were no pregnancies. However, there was reappearance of sperm in azoospermic patients, with one pregnancy. 49 A phase 3, multicenter study was recently performed in 1045 Chinese men undergoing monthly injections of 500 mg TU in tea seed oil for 30 months. All subjects had fathered at least one child in the past 2 years and had two normal semen analyses. Suppression was defined as azoospermia or o1 million sperms per ml. The cumulative contraception failure rate was 1.1 per 100 men (nine pregnancies), 4.8% patients did not achieve suppression and 1.3% of subjects had post-suppression sperm rebound. Treatment was well tolerated and spermatogenesis recovered to normal reference levels in all but two subjects following a 15-month recovery period. The authors concluded that monthly injection of TU is a safe, very effective and reversible contraceptive method in a high proportion of healthy fertile Chinese men. 50 Studies with testosterone buciclate, another longacting testosterone derivative were initially performed by the WHO collaborating center and showed moderate suppression of spermatogenesis at a dose of 1200 mg i.m. per month. This study, which was conducted in 1995, was among the first to show minimal side effects from this long-acting, easily administered testosterone derivative. This trial helped to set the stage for future investigation combining long-acting testosterone with progesterone derivatives. 51 Synthetic androgens have been tested as well. A dose response trial of 7a-methyl-19-nortestosterone (MENT) was initiated in 35 healthy volunteers to assess effects of serum gonadotropins and sperm production. 52 This synthetic androgen is more potent than testosterone, is resistant to 5 a-reduction and has diffusion characteristics that make it wellsuited for a depot implant. Initial data showed relatively good efficacy, but typical testosteronerelated side effects. Suvisaari et al. 53 and others have shown that MENT has a short half-life and is not suitable for long-term injection and does not show significant FSH suppression. Dimethandrolone undecanoate is another potent synthetic androgen with some progestational activity that represents an orally active substance that appears to suppress LH levels in vitro and in rabbit models. Structurally similar to MENT, it may be resistant to breakdown by 5a-reductase allowing it to maintain muscle mass without stimulating prostate growth. Preliminary animal data suggest that due to its combined androgen and progestin effects, dimethandrolone undecanoate may offer a single, reversible contraceptive agent for men. 54 Newer delivery systems have been approved by the US Food and Drug Administration for the treatment of hypogonadism. Whether men would tolerate daily gel application of testosterone may be a barrier to its widespread use, however recent studies combining testosterone gel with other agents will be presented later.
Testosterone alone has side effects, including acne and oily skin, mood changes, increased hemoglobin and hematocrit, weight gain, decrease in testicular volume, sleep apnea, gynecomastia and possible effects on cholesterol. There are no longterm data with testosterone use and normal men 1 . Phase 2 studies evaluating efficacy should use WHO sperm concentration parameters and the goal should be suppression o or ¼ to 1 million sperms per ml 2. After cessation of therapy, patients need to be followed until normal fertility is restored (criteria used is 20 million sperms per ml) 3. Inclusion criteria must include men with sperm concentrations 420 million per ml 4. Open-label, noncomparative contraceptive efficacy studies are acceptable if the primary end point is not susceptible to bias, e.g., pregnancy rate 5. For efficacy, two independent phase 3 trials for 1 year from suppression to o1 million per ml should include 200 men/couples per trial 6. For safety, new agents require studies with 300-600 men for 6 months at the intended combination and dose, 100 men exposed for 1 year and 1500 men in phase 1-3 studies at a minimum 7. Long-term safety will be monitored by post-marketing surveillance 8. Laboratory data need to be performed under strict quality control Update on male hormonal contraception GJ Manetti and SC Honig regarding prostate symptoms, growth or cancer. In an era of fear of using medications on relatively healthy individuals, acceptability of routine use may be a major concern, given recent data on medical treatment of menopause with estrogen/ progestin therapy. In addition, anabolic steroids are a controlled substance and regulation of this industry is very strict at this time. Abuse of these drugs could easily become prevalent with its widespread use and availability for contraception.
Although data suggest that testosterone therapy will create a milieu of oligospermia and/or azoospermia in most cases, its reliability is clearly uncertain at this point. The efficacy bar has been set very high with 'the pill'. Higher efficacy with fewer short-and long-term side effects will need to be achieved to make use of testosterone alone a viable option. In addition, close follow-up with regular semen analyses is necessary as there may be breakthroughs in sperm suppression. However, the use of testosterone with other agents may have more promise. It is not, completely clear why either testosterone alone, or in combination does not suppress spermatogenesis completely or why it results in evidence of 'breakthrough' sperm production. Theories suggested are incomplete suppression of FSH and persistent or episodic incomplete suppression of intratesticular testosterone that allows for low levels of sperm production. 42 Recent studies have shown increased levels of insulin-like factor 3 (INSL-3) 55 or increased fat content 49 in incompletely suppressed patients.
Combination therapy
Significant side effects and lack of high efficacy with testosterone alone have pushed researchers toward combination therapy. The goal of combination therapy is to create sterility effectively while using a lower-dose testosterone to maintain physiological levels and lessen side effects.
Testosterone and progestins
Progestins have been used in multiple small studies of men for suppression of spermatogenesis and testosterone production. Progestins used alone result in significant side effects such as loss of libido and erectile dysfunction. The mechanism of action of progestins is thought to be either negative feedback on the pituitary-gonadal axis, inhibition of LH receptor expression or direct effects on sperm. 56, 57 Progestins alone cannot suppress spermatogenesis in dosages tolerable for administration and without significant side effects. However, by combining lower doses of progestins with testosterone supplementation to restore exogenous testosterone, safety and efficacy may be improved and side effects lessened.
Medroxyprogesterone acetate (MPA and depot MPA)
Since the 1970s, the contraceptive efficacy of MPA has been studied. 58 Unlike studies on testosterone monotherapy, there are few randomized, multicenter, large population studies evaluating efficacy of testosterone/progestin preparations. 59 A review of MPA/testosterone preparations showed that only 67% of patients receiving MPA with different testosterone preparations achieved azoospermia. 60 The 1993 WHO study comparing testosterone alone and 19-nortestosterone with depot MPA showed consistent azoospermia in 95.6 and 97.8%, respectively, in 90 Indonesian men. 61 On the basis of this data, it was not clear if the effect was from testosterone alone or combination therapy. Subsequent studies in 55 men with testosterone implants and depot MPA showed suppression to o1 million sperms per ml in 94% of patients with no pregnancies in this suppression subgroup. 62 Median time to counts returning to 20 million sperms per ml was 5 months, but return to baseline numbers was much longer, suggesting an accumulation of drug in adipose tissue. These studies were conducted in the Asian population only. Recently, two papers reporting on the same group of patients studied 38 men with testosterone gel and depot MPA for sperm suppression and evaluated patient acceptability of this combination. 63, 64 Over 90% of patients had sperm suppression o1 million per ml, but acceptability was low, with only 45% saying they would use it if commercially available, one-third of the patients said it would interfere with their daily routine and questionnaire data showing mild changes in overall satisfaction with sexual activity and ejaculatory function. Interestingly, a subgroup of patients received GnRH antagonist, but there was no additive effect in terms of sperm suppression. A recent study by the same group looked at factors that might differentiate azoospermic groups from nonazoospermic groups. 55 Amory et al. performed a retrospective analysis of male hormone contraceptive studies and found that end of treatment INSL-3 levels were significantly increased in the nonazoospermic subgroup. 55 INSL-3 is a peptide hormone that appears to be almost exclusively produced by Leydig cells and can be relatively easily measured in serum by immunoassay. Although the exact role/ function of INSL-3 remains unclear, administration of this substance to mice has been shown to prevent apoptosis of male germ cells in the setting of FSH/ LH deficiency. 65 However, although INSL-3 may be a useful target for refining treatment, further Update on male hormonal contraception GJ Manetti and SC Honig investigation is still required to better understand and corroborate this interesting association between INSL-3 and nonazoospermic men and its potential application to the development of a hormonal contraceptive for men.
Cryproterone acetate
Cryproterone acetate is an active antiandrogen with progestin effects. It has been studied as hormone deprivation for prostate cancer. It has profound effects on libido, energy and decrease in hematocrit. Multiple studies [66] [67] [68] [69] [70] [71] [72] have been performed with combination cryproterone acetate and TE or TU. Doses ranging from 25 to 100 mg per day have suppressed spermatogenesis, but side effects have precluded subsequent studies. It has been postulated that antiandrogens may work well to suppress the effects of residual intratesticular testosterone not suppressed by other means. 38 
Levonorgestrel
Several small studies 60, [73] [74] [75] have been performed with levonorgestrel. This progestin is either an oral or implant preparation. Unfortunately, the studies performed with combination of levonorgestrel and testosterone resulted in only partial suppression of spermatogenesis even in the Asian population. The concept of a two-implant preparation of progesterone/ testosterone is appealing, but data for efficacy at the present time are lacking with this progestin.
Desogestrel and etonogestrel
Desogestrel is a potent oral progestin that is converted to the active agent, etonogestrel. Initial small studies performed with doses of 75, 150 and 300 mg per day showed variable results. A two-center study in Scotland and China with oral desogestrel 300 mg p.o. per day and 400 mg depot testosterone s.c. pellets led to suppression of spermatogenesis with azoospermia in 100% men. 76 There was noted to be a rise in high-density lipoprotein and weight gain. A subsequent study of 21 African men administered desogestrel and testosterone pellets showed similar results, but slightly less complete suppression with no negative effects on lipoprotein or hemoglobin. 58 Another study with 15 patients taking etonogestrel and testosterone pellets at 3-month intervals resulted in azoospermia in all subjects by 28 weeks. 77 A subsequent larger study (n ¼ 130) with the same investigators showed excellent sperm suppression with combination testosterone/progesterone implant when used monthly. 78 The combination of this two-drug pellet given every 3 months is a very palatable option for patients. A multicenter phase 2 trial was initiated in 2003, but terminated in 2006 by Schering-Organon for unclear reasons.
To minimize side effects, MENT has been combined with etonogestrel implants, hoping to decrease the dosage of MENT required to suppress spermatogenesis and eliminate some of the undesirable testosterone-related side effects. However, a recent study by Walton et al. 79 comparing MENT and testosterone in combination with etonogestrel implants in healthy men showed that suppression of spermatogenesis was inconsistent over time in the MENT/etonogestrel group, and still associated with persistent undesirable side effects (for example, reduced libido).
Dienogest
Dienogest is a progestin with a lower degree of antiandrogenic and estrogenic activities. Preliminary data suggest that it can suppress gonadotropins without adverse side effects. 80 A study was conducted in rats using a combination of dienogest and TU monthly injection that showed 100% contraceptive efficacy and complete arrest of spermatogenesis. These data were based on findings of lack of sperm in the rat epididymis and suppression of spermatogenesis in testis tissue. No negative effects of lipid profiles were seen. 81 However, there is minimal data available on sperm suppression in humans and further investigation is needed.
Norethisterone, nestorone gel
A depot female contraceptive with similar effects to TU makes this combination attractive for male contraception. A study conducted in 1988 showed suppression with a combination of oral norethisterone and TU. 82 Subsequent studies have shown high efficacy in a small group of Caucasian patients (74 total patients) with either oral or i.m. norethisterone and TU. 83, 84 8-week intervals of treatment had a higher azoospermic rate than 12-week treatment. No short-term changes in the prostate were seen. Longer-term studies are necessary to better evaluate changes in prostate size, PSA and so on. This combination is very attractive for a depot, as the 8-week injection of both testosterone and norethisterone is highly efficacious in a potentially single injection.
A recent clinical trail by Mahabadi et al. 85 showed that transdermal Nesterone and a relatively high dose of testosterone gel (10 g; Testim) had an additive effect on gonadotropin suppression. This randomized, multicenter, unmasked trial showed that the gel applications were well tolerated with Update on male hormonal contraception GJ Manetti and SC Honig few short-term adverse effects. The effects on cholesterol were mixed with a small drop in lowdensity lipoprotein and high-density lipoprotein. Because Nesterone is a progestin without estrogenic or androgenic activity, it represents a noteworthy candidate to augment the effectiveness of testosterone alone. A sperm suppression study with this regimen is planned.
Testosterone and GnRH analogues (agonists and antagonists)
Gonadotropin-releasing hormone is released in a pulsatile manner that is thought to be responsible for the episodic release of LH and FSH. GnRH agonists work by having paradoxical antigonadotropic effects through the downregulation of GnRH after an initial GnRH surge. GnRH antagonists cause competitive inhibition of GnRH receptors. They are familiar to clinicians for regulation of ovulation induction, treatment of advanced prostate cancer and endometriosis.
There have been 12 clinical trials with different GnRH agonists and testosterone resulting in a combined 23% suppression to azoospermia in 106 patients. 86, 87 It appears that the lack of suppression is related to breakthrough of FSH secretion. Therefore, at this point, this combination has not been actively pursued.
However, trials combining TE and GnRH antagonists seem to have better results. Several studies dating back to the early 1990s [88] [89] [90] [91] [92] suggest a rapid onset of suppression of spermatogenesis to azoospermia. This group of studies, each with small populations, suggested a good response to this combined therapy. When GnRH was stopped, and maintenance was performed with testosterone alone, suppression of spermatogenesis was not maintained. 93 Initial trials were with short-acting GnRH antagonists with local side effects such as significant irritation at injection site. With the longer-acting GnRH antagonists available having less local side effects, this therapy may take on a more critical role in the future.
GnRH/Gonadotropin vaccines
Immunomodulation of the reproductive system of animals has been under investigation for many years in the area of fertility control in animals such as rabbits, mice, cattle and subhuman primates for many years. The ideal target for a male contraceptive vaccine remains an interesting area of research that has undergone significant advances due to our improved understanding of gonadotropin feedback mechanism. As seen in Figure 1 , as GnRH stimulates secretion of gonadotropic hormones, it is logical that the immunoneutralization of GnRH would prevent endogenous GnRH from binding to its receptors and cause gonadal atrophy in adults, such as sprematogenic arrest and libido loss. 94 Several attempts have been made to couple mammalian GnRH, a nonimmunogenic peptide, to carrier proteins such as tetanus and diphtheria toxoids to enhance the bioefficacy of the antibodies produced. 95 Anti-GnRH vaccines have been tested for control of prostate cancers in India, in hopes of cutting off androgen support to prostate cancer cells. 96 Although there have been reports of contraceptive efficacy in male dogs, there have been no successful structured studies in male nonhuman primates that have carefully evaluated such a contraceptive vaccine. 95 Other possible vaccine targets include gonadotropins and gonadotropin receptors. Human FSH and ovine FSH are the two such candidate antigens. Attempts were made to use hFSH linked to cholera toxin and interleukin to produce effective antibodies. The immunization using hFSH caused a 75-100% decrease in sperm counts in the ejaculate. The fertility of male monkeys after hFSH immunization was significantly reduced, as described as loss in spermatozoa ability to penetrating hamster ova assay. 95 Even though FSH-based vaccines may not lead to azoospermia, there seems to be increasing evidence that a reduction in the quality of sperm combined with oligospermia may represent a reasonable marker for male contraception as a measure of infertility. Furthermore, using FSH protein fragments instead of GnRH-or LH-based vaccines does not require exogenous testosterone supplementation to maintain accessory gland function and libido. 95 Periodic vaccination as a method for male contraception represents a promising area of research and continues to be refined through the use of better adjuvant compounds.
Selective androgen receptor modulators
Selective androgen receptor modulators or SARMs mimic the central and peripheral androgenic and anabolic effects of testosterone and are being trialed for treatment of prostate disease. Although steroidal SARMs, such as MENT, did not effectively maintain sperm suppression, recent animal models suggest that nonsteroidal SARMs may hold promise. In rat models, SARM c-6 was found to induce significant suppression of spermatogenesis. 97 A study on rats showed that a structurally modified SARM, (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide (S-23), combined with estradiol benzoate was an effective and reversible regimen for suppressing spermatogenesis in male rats. 98 These oral, synthetic nonsteroidal molecules have the potential to mimic steroids and suppress gonadotropin without unwanted side effects. The Update on male hormonal contraception GJ Manetti and SC Honig animal studies serve as interesting models for testing in humans as either primary or adjunctive therapy. Although these compounds appear to have an interesting mechanism of action, there have not been any clinical trials with these agents to date.
Follow-up semen analysis studies
For a contraception method to be effective and reliable with a reversible method, follow-up semen analysis data need to be readily available. With vasectomy, once one or two post-vasectomy semen analyses show no sperm, typically no further followup is necessary. However some partners of men may request or require regular semen analysis testing. Historically, this required a doctor's visit or lab drop off. Furthermore, as men's participation in the contraceptive process grows and population growth continues to represent a global concern, the demand for safer, cheaper and more reversible methods will increase as well. As we move toward this goal, a useful adjunct to measuring sperm suppression with a contraceptive may be the home immunodiagnostic SpermCheck s ContraVac, Charlottesville, VA, USA; Vasectomy kit. This home kit uses monoclonal antibodies that recognize the sperm-specific acrosomal protein SP-10. Although the second WHO study noted a significant difference in pregnancy rates between azoospermic patients and severely oligospermic (0.1-3 million sperms per ml) patients, most male contraceptives target sperm concentrations o 1 million sperms per ml. In a cohort study of 144 post-vasectomy semen samples, the device registered a negative result in sperm concentrations of approximately 385 000 sperms per ml. The test was positive in 100% of cases if sperm concentrations were greater than 385 000. More importantly, the device had a negative predictive value of 97% below this value. 99 The availability of a home test for easy confirmation and low-cost follow-up will make this a more palatable option to the average couple. Although this test will not differentiate between motile and nonmotile sperms (and therefore is not recommended after vasectomy), if we are testing for a value of less than 1 million sperms per ml, it should be very reliable.
Summary
In summary, male hormonal contraception is approaching the high bar set by 'the pill' and vasectomy. However, much more work is necessary to clarify the best combination therapy, timing, efficacy, and short-and long-term safety before it will reach phase 3 trials. The 10th summit meeting on Hormonal Male Contraception (2006) has agreed on the following criteria listed in Table 1 for studies on treatment modalities. 35 Although vasectomy and condoms will likely remain very popular options, the hope for a nonsurgical treatment for male contraception will certainly remains possible in the future. Furthermore, as men's participation in the contraceptive process grows and population growth continues to represent a global concern, the demand for safer, cheaper and more reversible methods will increase as well. However, the long-term effects and male health implications of sustained hormonal supplementation remain persistent obstacles in the search for an effective and tolerable 'male pill'.
